Chemoradiotherapy of NSCLC Stage IIIB

Status Completed

Clinical Trial Summary

To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.

Clinical Trial Description

Chemotherapy:

C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m²

Radiotherapy:

66 Gy with 33 fractions (2 Gy/fraction, 1 fraction/day, 6,5 weeks) High energy Photons X (>= 9MV) ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00198432
Study type	Interventional
Source	Intergroupe Francophone de Cancerologie Thoracique
Contact
Status	Completed
Phase	Phase 2
Start date	March 2002
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Recruiting	`NCT04467801` - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy	Phase 2
Active, not recruiting	`NCT04027647` - Phase 2 Study of Dacomitinib in NSCLC	Phase 2
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Recruiting	`NCT05132218` - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2
Recruiting	`NCT05281406` - Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)	Phase 2
Active, not recruiting	`NCT04223596` - Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients	Phase 2
Not yet recruiting	`NCT06374160` - Exercise in Patients With Advanced Non-small Cell Lung Cancer	N/A
Recruiting	`NCT05652868` - Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer	Phase 1
Terminated	`NCT03805841` - Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions	Phase 2
Withdrawn	`NCT05212922` - A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC	Phase 2
Active, not recruiting	`NCT04932343` - Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
Withdrawn	`NCT03231475` - Phase I Study of SPH1188-11 in NSCLC	Phase 1
Withdrawn	`NCT03628144` - Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04865250` - Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC	Phase 2
Active, not recruiting	`NCT05816499` - Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)	Phase 1/Phase 2
Active, not recruiting	`NCT03620669` - 1st Line Durvalumab in PS 2 NSCLC Patients	Phase 2
Not yet recruiting	`NCT03594682` - Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study	N/A
Completed	`NCT03515252` - Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer	Phase 1